In The News Posted October 2, 2021 Share Posted October 2, 2021 NORTH CHICAGO, Ill., Oct. 2, 2021 /PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI®) in Crohn's disease, upadacitinib (RINVOQ®) in ulcerative colitis and HUMIRA® (adalimumab) in inflammatory bowel disease (IBD) will be presented as live...View the full article Quote Link to comment Share on other sites More sharing options...
Recommended Posts